- Home
- AMPL vs KURA Comparison
AMPL vs KURA Comparison
Compare AMPL & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMPL
- KURA
- Stock Information
- Founded
- AMPL 2012
- KURA 2014
- Country
- AMPL United States
- KURA United States
- Employees
- AMPL N/A
- KURA N/A
- Industry
- AMPL EDP Services
- KURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AMPL Technology
- KURA Health Care
- Exchange
- AMPL Nasdaq
- KURA Nasdaq
- Market Cap
- AMPL 1.3B
- KURA 1.3B
- IPO Year
- AMPL 2021
- KURA N/A
- Fundamental
- Price
- AMPL $9.59
- KURA $15.92
- Analyst Decision
- AMPL Hold
- KURA Strong Buy
- Analyst Count
- AMPL 7
- KURA 7
- Target Price
- AMPL $11.00
- KURA $29.83
- AVG Volume (30 Days)
- AMPL 451.7K
- KURA 821.5K
- Earning Date
- AMPL 11-07-2024
- KURA 11-07-2024
- Dividend Yield
- AMPL N/A
- KURA N/A
- EPS Growth
- AMPL N/A
- KURA N/A
- EPS
- AMPL N/A
- KURA N/A
- Revenue
- AMPL $292,544,000.00
- KURA N/A
- Revenue This Year
- AMPL $9.28
- KURA N/A
- Revenue Next Year
- AMPL $7.97
- KURA N/A
- P/E Ratio
- AMPL N/A
- KURA N/A
- Revenue Growth
- AMPL 8.29
- KURA N/A
- 52 Week Low
- AMPL $7.37
- KURA $9.06
- 52 Week High
- AMPL $14.42
- KURA $24.17
- Technical
- Relative Strength Index (RSI)
- AMPL 51.52
- KURA 34.68
- Support Level
- AMPL $9.62
- KURA $16.55
- Resistance Level
- AMPL $11.00
- KURA $19.73
- Average True Range (ATR)
- AMPL 0.48
- KURA 0.98
- MACD
- AMPL 0.02
- KURA -0.05
- Stochastic Oscillator
- AMPL 31.22
- KURA 8.86
About AMPL Amplitude Inc.
Amplitude Inc is a Software company that provides a Digital Analytics Platform that helps companies analyze their customer behavior within digital products. The Company delivers its application over the Internet as a subscription service using a software-as-a-service (SaaS) model and also it offers customer support related to initial implementation setup, ongoing support services, and application training. The company generates revenue primarily through selling subscriptions to the platform. The company derives a majority of its revenue from the United States.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.